Literature DB >> 20025540

Clinical and cytological features predictive of malignancy in thyroid follicular neoplasms.

Carrie C Lubitz1, William C Faquin, Jingyun Yang, Michal Mekel, Randall D Gaz, Sareh Parangi, Gregory W Randolph, Richard A Hodin, Antonia E Stephen.   

Abstract

BACKGROUND: The preoperative diagnosis of malignancy in nodules suspicious for a follicular neoplasm remains challenging. A number of clinical and cytological parameters have been previously studied; however, none have significantly impacted clinical practice. The aim of this study was to determine predictive characteristics of follicular neoplasms useful for clinical application.
METHODS: Four clinical (age, sex, nodule size, solitary nodule) and 17 cytological variables were retrospectively reviewed for 144 patients with a nodule suspicious for follicular neoplasm, diagnosed preoperatively by fine-needle aspiration (FNA), from a single institution over a 2-year period (January 2006 to December 2007). The FNAs were examined by a single, blinded pathologist and compared with final surgical pathology. Significance of clinical and cytological variables was determined by univariate analysis and backward stepwise logistic regression. Odds ratios (ORs) for malignancy, a receiver operating characteristic curve, and predicted probabilities of combined features were determined.
RESULTS: There was an 11% incidence of malignancy (16/144). On univariate analysis, nodule size >OR=4.0 cm nears significance (p = 0.054) and 9 of 17 cytological features examined were significantly associated with malignancy. Three variables stay in the final model after performing backward stepwise selection in logistic regression: nodule size (OR = 0.25, p = 0.05), presence of a transgressing vessel (OR = 23, p < 0.0001), and nuclear grooves (OR = 4.3, p = 0.03). The predicted probability of malignancy was 88.4% with the presence of all three variables on preoperative FNA. When the two papillary carcinomas were excluded from the analysis, the presence of nuclear grooves was no longer significant, and anisokaryosis (OR = 12.74, p = 0.005) and presence of nucleolus (OR = 0.11, p = 0.04) were significantly associated with malignancy. Excluding the two papillary thyroid carcinomas, a nodule size >or=4 cm, with a transgressing vessel and anisokaryosis and lacking a nucleolus, has a predicted probability of malignancy of 96.5%.
CONCLUSIONS: A combination of larger nodule size, transgressing vessels, and specific nuclear features are predictive of malignancy in patients with follicular neoplasms. These findings enhance our current limited predictive armamentarium and can be used to guide surgical decision making. Further study may result in the inclusion of these variables to the systematic evaluation of follicular neoplasms.

Entities:  

Mesh:

Year:  2010        PMID: 20025540     DOI: 10.1089/thy.2009.0208

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  19 in total

1.  Predictors of malignancy in patients with cytologically suspicious thyroid nodules.

Authors:  M Regina Castro; Rachel P Espiritu; Rebecca S Bahn; Michael R Henry; Hossein Gharib; Pedro J Caraballo; John C Morris
Journal:  Thyroid       Date:  2011-10-18       Impact factor: 6.568

2.  Value of ultrasound and cytological classification system to predict the malignancy of thyroid nodules with indeterminate cytology.

Authors:  Frederico Fernandes Ribeiro Maia; Patrícia S Matos; Elizabeth J Pavin; José Vassallo; Denise E Zantut-Wittmann
Journal:  Endocr Pathol       Date:  2011-06       Impact factor: 3.943

3.  Predictive value of cytologic atypia in indeterminate thyroid fine-needle aspirate biopsies.

Authors:  Meredith A Kato; Daniel Buitrago; Tracy-Ann Moo; Xavier M Keutgen; Raza S Hoda; Joseph A Ricci; Paul J Christos; Grace Yang; Thomas J Fahey; Rasa Zarnegar
Journal:  Ann Surg Oncol       Date:  2011-03-22       Impact factor: 5.344

4.  Predictive factors of malignancy in thyroid nodules with a cytological diagnosis of follicular neoplasm.

Authors:  Seong Hyeon Lee; Jeong Su Baek; Joo Young Lee; Jung Ah Lim; Soo Youn Cho; Tae Hyun Lee; Yun Hyi Ku; Hong Il Kim; Min Joo Kim
Journal:  Endocr Pathol       Date:  2013-12       Impact factor: 3.943

5.  Follicular-derived neoplasms: morphometric and genetic differences.

Authors:  A Proietti; C Sartori; N Borrelli; R Giannini; G Materazzi; P Leocata; R Elisei; P Vitti; P Miccoli; F Basolo
Journal:  J Endocrinol Invest       Date:  2013-07-23       Impact factor: 4.256

Review 6.  Clinical characteristics as predictors of malignancy in patients with indeterminate thyroid cytology: a meta-analysis.

Authors:  Pierpaolo Trimboli; Giorgio Treglia; Leo Guidobaldi; Enrico Saggiorato; Giuseppe Nigri; Anna Crescenzi; Francesco Romanelli; Fabio Orlandi; Stefano Valabrega; Ramin Sadeghi; Luca Giovanella
Journal:  Endocrine       Date:  2013-10-03       Impact factor: 3.633

7.  DNA copy number variations characterize benign and malignant thyroid tumors.

Authors:  Yan Liu; Leslie Cope; Wenyue Sun; Yongchun Wang; Nijaguna Prasad; Lauren Sangenario; Kristen Talbot; Helina Somervell; William Westra; Justin Bishop; Joseph Califano; Martha Zeiger; Christopher Umbricht
Journal:  J Clin Endocrinol Metab       Date:  2013-01-23       Impact factor: 5.958

8.  Risk Stratification in Patients With Follicular Neoplasm on Cytology: Use of Quantitative Characteristics and Sonographic Patterns.

Authors:  Ming-Hsun Wu; Kuen-Yuan Chen; Min-Shu Hsieh; Argon Chen; Chiung-Nien Chen
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-30       Impact factor: 5.555

9.  A Bayesian mixture model for changepoint estimation using ordinal predictors.

Authors:  Emily Roberts; Lili Zhao
Journal:  Int J Biostat       Date:  2021-04-06       Impact factor: 1.829

Review 10.  Thyroid nodule management: clinical, ultrasound and cytopathological parameters for predicting malignancy.

Authors:  Frederico F R Maia; Denise Engelbrecht Zantut-Wittmann
Journal:  Clinics (Sao Paulo)       Date:  2012-08       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.